Microcirculation

Celluma Light Therapy Introduces the RESTORE Hair Therapy System

Retrieved on: 
Thursday, March 14, 2024
DHT, Vitamin, Adenosine triphosphate, Serum, Inflammation, Zinc, Hair loss, Glycine, Scalp, ATP, FDA, Microcirculation, Peptide, Cosmetics

TUSTIN, Calif., March 14, 2024 /PRNewswire/ -- BioPhotas, Inc., the makers of Celluma Light Therapy and market leader in therapeutic LED light therapy devices, announced today the launch of the RESTORE Hair Serum, an optimized scalp and hair formulation that complements the award-winning Celluma RESTORE LED device to provide a complete hair-restoration solution.

Key Points: 
  • TUSTIN, Calif., March 14, 2024 /PRNewswire/ -- BioPhotas, Inc., the makers of Celluma Light Therapy and market leader in therapeutic LED light therapy devices, announced today the launch of the RESTORE Hair Serum, an optimized scalp and hair formulation that complements the award-winning Celluma RESTORE LED device to provide a complete hair-restoration solution.
  • "It's an amazingly elegant formulation that is clear and easily absorbed into the scalp so that it can be used daily to maximize the Celluma Light Therapy results."
  • For the growing number of professionals and individuals achieving significant and visible results with the FDA-cleared Celluma RESTORE Light Therapy device for hair restoration, this serum is an ideal complement for use between each light therapy treatment.
  • According to Mr. Cluff, "the Celluma RESTORE light therapy device has been available since receiving FDA-clearance for hair restoration in 2021.

Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill

Retrieved on: 
Wednesday, August 23, 2023
Hair, Collagen, Stem cell factor, Face, Ki-67, Oxygen, Survival, Nail, Hair follicle, DHT, Multimedia, Signal, Hair loss, Neck, Scalp, GHK, Capillary, Plasma, FGF2, Peptide, Blood, Testosterone, Microcirculation, Biotin, Health, Exosome, Human, Melanocyte, SCF, Saliva, Wound healing, Cosmetics, Dietary supplement, Vaccine, Copper, Sulfur, Minoxidil

SEOUL, South Korea and NEW YORK, Aug. 23, 2023 /PRNewswire/ -- Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill.

Key Points: 
  • SEOUL, South Korea and NEW YORK, Aug. 23, 2023 /PRNewswire/ -- Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill.
  • HAIRNA Exosome Hair Fill is developed with Maypharm's exclusive technology for scalp rejuvenation and hair growth.
  • In addition to HAIRNA Exosome Hair Fill, Maypharm has launched such popular human stem cell products such as 2XSOME for face and neck.
  • Whether you are looking to improve your appearance or to regain self-confidence, HAIRNA Exosome Hair Fill is a solution that is hard to beat.

Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill

Retrieved on: 
Wednesday, August 23, 2023
Hair, Collagen, Stem cell factor, Face, Ki-67, Oxygen, Survival, Nail, Hair follicle, DHT, Signal, Hair loss, Neck, Scalp, GHK, Capillary, Plasma, FGF2, Peptide, Blood, Testosterone, Microcirculation, Biotin, Health, Exosome, Human, Melanocyte, SCF, Saliva, Wound healing, Cosmetics, Dietary supplement, Vaccine, Copper, Sulfur, Minoxidil

SEOUL, South Korea and NEW YORK, Aug. 23, 2023 /PRNewswire/ -- Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill.

Key Points: 
  • SEOUL, South Korea and NEW YORK, Aug. 23, 2023 /PRNewswire/ -- Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill.
  • HAIRNA Exosome Hair Fill is developed with Maypharm's exclusive technology for scalp rejuvenation and hair growth.
  • In addition to HAIRNA Exosome Hair Fill, Maypharm has launched such popular human stem cell products such as 2XSOME for face and neck.
  • Whether you are looking to improve your appearance or to regain self-confidence, HAIRNA Exosome Hair Fill is a solution that is hard to beat.

Millions across the world live with low back pain, but addressing major risk factors like smoking, obesity and workplace ergonomics could curb the trend, research shows

Retrieved on: 
Friday, July 28, 2023
Obesity, Smoking, Health, Low back pain, Disability, Spine, Woman, Research, Risk, Falls, Google Images, Pain, Back pain, Man, Patient, Microcirculation, Joint, Global Burden of Disease Study, Birth control, Poultry farming

“Burden” refers to a combination of how common low back pain is and how much health loss it leads to.

Key Points: 
  • “Burden” refers to a combination of how common low back pain is and how much health loss it leads to.
  • Our study found that if society could directly address three major risk factors – obesity, smoking and workplace ergonomic factors – it could cut the burden of low back pain by 39%.
  • Similarly, obesity is associated with other unhealthy lifestyle factors, all of which can increase the risk of low back pain.
  • Given our finding that hundreds of millions of people live with low back pain, it’s clear that more research is needed to identify effective preventive strategies.

Astonishing the World Congress of Dermatology, Chinese Brand WINONA Scales New Heights

Retrieved on: 
Wednesday, July 12, 2023
Cream, Evidence-based medicine, Orient, Ministry of Education and Science (Somaliland), Kunming Medical University, Atopic dermatitis, First Affiliated Hospital of Xinjiang Medical University, Teaching hospital, Congress, Canadian International Council, Melasma, Natural product, R, University, JAMA Dermatology, Research, Knowledge, Hospital, Configuration Management Specialist Group, CERT, Skin, Safety, Skin care, Vascular disease, Ministry, Ecology, Hyperpigmentation, Intelligence, First Affiliated Hospital of Zhengzhou University, Inflammation, Microcirculation, Education, Retail, Cosmetics, Management, Renewable energy, Tea, Venereology, Dermatology, WCD

In addition to delivering Chinese brand image to the world, WINONA also jointly promoted the development of the broader skin health ecology alongside global brands.

Key Points: 
  • In addition to delivering Chinese brand image to the world, WINONA also jointly promoted the development of the broader skin health ecology alongside global brands.
  • For a Chinese brand to stand firm, it must possess the ability and confidence to absorb advanced industry technologies, and step onto the world stage to engage in professional dialogues.
  • In recent years, WINONA, as a representative of Chinese brands, has frequently made appearances on the international stage, showcasing the unique charm of Chinese skincare products.
  • In WINONA, people see a sense of quality, leadership, and international appeal conveyed by a Chinese brand.

The World Congress of Dermatology Closed, WINONA Propels Chinese Brand Appeal onto the International Stage

Retrieved on: 
Wednesday, July 12, 2023
Cosmetics, Retail, General Health, Health, Cream, Skin care, Ministry of Education, Culture, Sports, Science and Technology, Melasma, Kunming Medical University, Skin, JAMA Dermatology, Atopic dermatitis, Research, First Affiliated Hospital of Xinjiang Medical University, Ministry, Congress, WCD, Canadian International Council, Microcirculation, Ecology, Hospital, Education, Hyperpigmentation, Dermatology, Venereology

On July 8th, the 25th World Congress of Dermatology (WCD), referred to as the "Olympics of the Dermatology," concluded in Singapore, with the Chinese top dermatology skin care brand WINONA emerging as the focus of the conference.

Key Points: 
  • On July 8th, the 25th World Congress of Dermatology (WCD), referred to as the "Olympics of the Dermatology," concluded in Singapore, with the Chinese top dermatology skin care brand WINONA emerging as the focus of the conference.
  • In addition to delivering Chinese brand image to the world, WINONA also jointly promoted the development of the broader skin health ecology alongside global brands.
  • At this WCD, Professor Philippe Humbert released the latest international observational results of WINONA products, reaffirming the effectiveness of two WINONA products including "WINONA Sensitiveness Relieving Moisturizing Tolerance-Extreme Cream".
  • As a leading international theory, it was released to the global community in English and has gained recognition from international dermatology experts.

China Industry-University-Research-Medicine Shines at the Top of the World: BOTANEE 2023 International Skin Health Summit Closed

Retrieved on: 
Wednesday, July 12, 2023
Cosmetics, Retail, Health, Other Health, General Health, Clinical Trials, Biotechnology, Cream, Prevalence, Skin care, Kunming Medical University, Dermatology, Acne, Atopic dermatitis, Multimedia, First Affiliated Hospital of Xinjiang Medical University, Risk, Microcirculation, Diagnosis, Ageing, AI, Capital Medical University, Hospital, AD, Annual report, Recurrence, R, Epidemiology, Conference, Pharmaceutical industry, WCD

After eight years, WINONA has now become the leading brand of functional skin care products in China.

Key Points: 
  • After eight years, WINONA has now become the leading brand of functional skin care products in China.
  • I hope that after four years, it will bring new impacts to WCD in terms of academic, technical, clinical and social impact. "
  • View the full release here: https://www.businesswire.com/news/home/20230711804321/en/
    2023 BOTANEE International Skin Health Summit (Photo: Business Wire)
    During the WCD World Dermatology Conference in Singapore, BOTANEE Group held the 2023 International Skin Health Summit simultaneously, bringing its four brands WINONA, WINONA Baby, AOXMED and Beforteen to the world stage for the first time, showing the professional strength of China's leading dermatology enterprises.
  • With the continuous iteration of the efficacy skin care market and consumer demand, BOTANEE has also been committed to promoting brand building.

AMIRO Celebrates International Day of Yoga with A New Approach to Enhance the Benefits of Face Yoga

Retrieved on: 
Tuesday, June 20, 2023
Exercise, Elasticity, International, Face, Facial muscles, Overalls, Ageing, Woman, Social media, Electrical muscle stimulation, EMS, Philosophy, Beauty, Radio frequency, Microcirculation, CIO, Courage, RF, Skin, Cosmetics, Yoga

Especially the increasingly popular Face Yoga, it is an exercise that many people incorporate into their daily routines to help maintain youth, vitality and beauty.

Key Points: 
  • Especially the increasingly popular Face Yoga, it is an exercise that many people incorporate into their daily routines to help maintain youth, vitality and beauty.
  • By partnering with multiple expert face yoga practitioners including Blush with me-Parmita, AMIRO aims to promote a more efficient and simplified way of practicing facial yoga.
  • To celebrate this event, AMIRO reintroduced its latest range of products that can act as the perfect partner to a great Yoga routine.
  • Specifically for Face Yoga practitioners, the highlighted products are perfectly suited to enhance the benefits of facial exercises.

ISHLT 2023 Annual Meeting Awards Showcase Advances in Treatment of Advanced Heart and Lung Disease

Retrieved on: 
Friday, June 2, 2023
Abstract, Society, University, UT, Lymphoproliferative disorders, Lung transplantation, Cancer, University of New South Wales, Research, Transplant, GA, University of Utah, Philip, Asian Americans Advancing Justice Southern California, Journal, Patient, Microcirculation, LVEDD, Heart failure, Stanford University School of Medicine, Heart transplantation, LVAD, Great Ormond Street Hospital, MCS, International Society, Dentistry, Medical device, Nursing, Birth control, Heart, Stanford University

Chicago, IL, June 02, 2023 (GLOBE NEWSWIRE) -- The International Society for Heart and Lung Transplantation 43rd Annual Meeting & Scientific Sessions included more than 1,250 presentations on improving outcomes for patients with advanced heart and lung disease from investigators from around the world.

Key Points: 
  • Chicago, IL, June 02, 2023 (GLOBE NEWSWIRE) -- The International Society for Heart and Lung Transplantation 43rd Annual Meeting & Scientific Sessions included more than 1,250 presentations on improving outcomes for patients with advanced heart and lung disease from investigators from around the world.
  • All conference abstracts are available in a special supplement to the Journal of Heart and Lung Transplantation’s April 2023 issue.
  • The team evaluated donor characteristics associated with heart acceptance in the USA and applied modern analytic methods to improve the prediction of heart acceptance.
  • Purpose: Heart transplant remains the gold standard treatment for patients with advanced heart failure.

Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, May 9, 2023
Transfer, Pancreatic cancer, Therapy, Conference call, Neoplasm, Medicines and Healthcare products Regulatory Agency, Glomerular filtration rate, New Jersey Economic Development Authority, Research, RNA, Immunotherapy, CD34, Trial of the century, Pharmaceuticals and Medical Devices Agency, Medication, Chemistry, Patient, PMDA, FREEDOM, Microcirculation, Kidney, CLI, DKD, Tumor microenvironment, Kidney disease, Disease, Pharmaceutical industry, Nursing, Conference

BASKING RIDGE, N. J., May 09, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provides a business update and reports financial results for the three months ended March 31, 2023.

Key Points: 
  • Conference call scheduled for today at 4:30 p.m. Eastern time
    BASKING RIDGE, N. J., May 09, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provides a business update and reports financial results for the three months ended March 31, 2023.
  • LSTA1 also has the potential to modify the tumor microenvironment, with the objective of making tumors more susceptible to immunotherapies.
  • The combination of LSTA1 with corresponding standards-of-care in other solid tumor indications is planned for clinical study commencing before the end of the second quarter of 2023.
  • Lisata will hold a live conference call today, May 9, 2023, at 4:30 p.m. Eastern time to discuss financial results, provide a business update and answer questions.